

TITULO	REVISTA	FI	Q/D	DOI	UT (Unique WOS ID)	Pubmed Id
Combining Wire Localization of Clipped Nodes with Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer: Preliminary Results from a Prospective Study	ANNALS OF SURGICAL ONCOLOGY	4,061	1	10.1245/s10434-020-08925-5	WOS:000553325900006	32725521
Differential Characteristics of HMGB2 Versus HMGB1 and their Perspectives in Ovary and Prostate Cancer	CURRENT MEDICINAL CHEMISTRY	4,184	2	10.2174/0929867326666190123120338	WOS:000540216200001	30674244
The HMGB1-2 Ovarian Cancer Interactome. The Role of HMGB Proteins and Their Interacting Partners MIEN1 and NOP53 in Ovary Cancer and Drug-Response	CANCERS	6,126	1	10.3390/cancers12092435	WOS:000581411700001	32867128
The Challenges and Opportunities of LncRNAs in Ovarian Cancer Research and Clinical Use	CANCERS	6,126	1	10.3390/cancers12041020	WOS:000535587400248	32326249
Heat Shock Protein 90 Chaperone Regulates the E3 Ubiquitin-Ligase Hakai Protein Stability	CANCERS	6,126	1	10.3390/cancers12010215	WOS:000516826700215	31952268
Regulation of Epithelial-Mesenchymal Plasticity by the E3 Ubiquitin-Ligases in Cancer	CANCERS	6,126	1	10.3390/cancers12113093	WOS:000593654700001	33114139
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus	CLINICAL & TRANSLATIONAL ONCOLOGY	2,737	3	10.1007/s12094-019-02191-y	WOS:000524244200014	31368078
Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus	CLINICAL & TRANSLATIONAL ONCOLOGY	2,737	3	10.1007/s12094-020-02518-0	WOS:000590483300001	33210237
Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology	CLINICAL & TRANSLATIONAL ONCOLOGY	2,737	3	10.1007/s12094-019-02211-x	WOS:000529952200005	31559582
A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus	CLINICAL & TRANSLATIONAL ONCOLOGY	2,737	3	10.1007/s12094-020-02300-2	WOS:000516249200001	32062835
The Role of the Liquid Biopsy in Decision-Making for Patients with Non-Small Cell Lung Cancer	JOURNAL OF CLINICAL MEDICINE	5,688	1	10.3390/jcm9113674	WOS:000593173900001	33207619
FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥ 3 circulating tumour cells: the randomised phase III VISNu-1 trial	ESMO OPEN	5,329	1	10.1136/esmoopen-2020-000944	WOS:000591346900001	33148620
Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation	CANCER EPIDEMIOLOGY	2,179	4	10.1016/j.canep.2020.101737	WOS:000565710000042	32450544
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial	JOURNAL OF CLINICAL ONCOLOGY	32,956	D1	10.1200/JCO.20.00505	WOS:000588411100004	32780660
Development of a Multicriteria Decision Analysis Framework for Evaluating and Positioning Oncologic Treatments in Clinical Practice	JCO ONCOLOGY PRACTICE			10.1200/JOP.19.00487	WOS:000533647400009	32160482
Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry	PLOS ONE	2,740	2	10.1371/journal.pone.0235848	WOS:000569367100012	32735623

Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study	SCIENTIFIC REPORTS	3,998	1	10.1038/s41598-020-63637-w	WOS:000560351700001	32385335
Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram	CLINICAL & TRANSLATIONAL ONCOLOGY	2,737	3	10.1007/s12094-019-02130-x	WOS:000514803600010	31073972
External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?	GASTRIC CANCER	7,088	1	10.1007/s10120-020-01116-x	WOS:000572609700002	32970266
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)	JOURNAL OF CLINICAL ONCOLOGY	32,956	D1	10.1200/JCO.19.00904	WOS:000508197300005	31804894
Serum Phospholipids Fatty Acids and Breast Cancer Risk by Pathological Subtype	NUTRIENTS	4,546	1	10.3390/nu12103132	WOS:000585299100001	33066483
Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population	ECANCERMEDICAL SCIENCE			10.3332/ecancer.2020.1020	WOS:000524981000001	32256703
First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study	JOURNAL OF GERIATRIC ONCOLOGY	2,761	3	10.1016/j.jgo.2020.06.003	WOS:000583348000011	32580916
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial	LANCET ONCOLOGY	33,752	D1	10.1016/S1470-2045(20)30453-8	WOS:000584488100044	32979984
First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial	CLINICAL & TRANSLATIONAL ONCOLOGY	2,737	3	10.1007/s12094-019-02151-6	WOS:000520849200006	31280434
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group	LUNG CANCER	4,702	2	10.1016/j.lungcan.2020.06.034	WOS:000571542700013	32682189
Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents	FRONTIERS IN ONCOLOGY	4,848	2	10.3389/fonc.2020.01677	WOS:000574262000001	33014837
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment	LUNG CANCER	4,702	2	10.1016/j.lungcan.2020.10.003	WOS:000598669100013	33096421
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial	LANCET ONCOLOGY	33,752	D1	10.1016/S1470-2045(20)30068-1	WOS:000540084200040	32224306
Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?	INTERNATIONAL JOURNAL OF COLORECTAL DISEASE	2,108	4	10.1007/s00384-020-03509-x	WOS:000516131800001	32062727